Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$163.81
▲ $2.39 (+1.5%)
Market data updated: 09/20 04:12 AM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$9.66B
Day Range
$159.01 - $163.84
52-Week Range
$73.16 - $191.62
Beta
—
Next Earnings
27.10.2026
Support
$143.11
Resistance
$191.62
GKOS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+90.8% (1Y)
Strengths: 9/28 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 32.3%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$9.40 vs. price $163.81 (-105.7%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
49
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
54
Quality
58
Value
38
Momentum
39
Risk
48
Sentiment
100
Fundamental
35
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Glaukos Corporation has primarily highlighted its strong stock performance and investor interest. The company’s shares have surged significantly—up **67% year-to-date**—driven by accelerating revenue and earnings growth, positioning it as a high-growth momentum stock. Analysts note its near **52-week high** and robust relative strength, while insider activity, including a recent **$2.48 million share sale**, has also been reported. The focus remains on its financial momentum and market outperformance over the past five years.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Glaukos Corporation. News trend score: 100. Reason: 11 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
34
🎯 Conviction (vs. Emotion)
41
Psychology
38
Fundamentals
35
Technical
39
Valuation
38
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+25%
Market Narrative
56
Fundamental Reality
41
Narrative Gap
+15
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests GKOS is experiencing **herding** as traders align with peers despite relative underperformance today. The narrative-reality gap (16 points) indicates optimism (57) exceeds tangible momentum, while euphoria persists due to long-term outperformance (+26.5%). Overconfidence may arise from ignoring price-momentum vs. EPS divergence (-6.4% vs. -0.2%). The key question: *Will traders double down on alignment or reassess fundamentals?*
Updated: 09/07/2026, 05:19 PM
What could change this?
👥 What the crowd believes
"Glaukos (GKOS) has outperformed the market over the past 5 years by 15.09% on an annualized basis producing an average annual return of 26.17%"
"BTIG analyst Ryan Zimmerman maintains Glaukos (GKOS) with a Buy and raises the price target from $193 to $202"
"Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues."
"GKOS fits a Minervini Trend Template + High Growth Momentum screen: ... near 52-week high"
📈 8D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Thorstein Veblen — 21/100
🗣️ Why do they disagree?
The stark divide in verdicts for GKOS reflects deep methodological contrasts between risk-focused and valuation-driven investors. At the top, Walter Bagehot’s near-perfect score highlights the company’s liquidity resilience, aligning with his credit-centric approach, while Samuel Armstrong Nelson’s favorable cycle position suggests a contrarian tilt toward oversold conditions. Meanwhile, Philip Fisher’s quality-focused score contrasts sharply with the lower-end verdicts from Graham (both Defensive and Enterprising) and Livermore, who dismiss it as statistically unappealing or counter-trend. The middle ground—where investors like Gerald Loeb, Morgan Housel, and Peter Lynch offer cautious but mixed views—reflects a blend of moderate risk tolerance and nuanced growth skepticism, while the bottom-tier scores from Marks (both risk and cycle) and Veblen underscore concerns about speculative overreach or late-stage market dynamics.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 93
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 75
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 54
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 50
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 48
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 48
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 46
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 43
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 43
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 39
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 32
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (3 bullish · 7 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
55.7%
Operating Margin
-39.3%
Net Margin
-37.0%
EBITDA Margin
-31.8%
ROE
-28.6%
ROA
-21.0%
ROIC
—
EPS
-$3.28
Cash
$90.81M
Total Debt
—
Current Ratio
4.69
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$163.81
Estimated Fair Value (DCF)
-$9.40
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-105.7%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
21.8%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 21.8% | $-27.35M | $-25.09M |
| 2 | 17.0% | $-32.00M | $-26.93M |
| 3 | 12.2% | $-35.89M | $-27.71M |
| 4 | 7.3% | $-38.52M | $-27.29M |
| 5 | 2.5% | $-39.48M | $-25.66M |
Base FCF (last actual year)
$-22.45M
Terminal Value
$-622.59M
Present Value of Terminal Value
$-404.64M
Enterprise Value
$-537.33M
Net Debt
$0
Equity Value
$-537.33M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$11.47
Tangible Book Value per Share (Tangible NAV)
$7.83
Sentiment based on basic keywords (not AI) — 11 positive, 9 neutral, 0 negative out of the last 20 articles.
Yahoo · 18.9.2026
Benzinga · 10.9.2026
Zacks · 3.9.2026
MT Newswires · 2.9.2026
Yahoo · 1.9.2026
Zacks · 1.9.2026
ChartMill · 1.9.2026
Yahoo · 28.8.2026
Zacks · 28.8.2026
Benzinga · 25.8.2026
Zacks · 20.8.2026
Benzinga · 20.8.2026
Benzinga · 20.8.2026
Zacks · 19.8.2026
Business Wire · 19.8.2026
MT Newswires · 14.8.2026
MT Newswires · 11.8.2026
Motley Fool · 8.8.2026
Zacks · 6.8.2026
Investor's Business Daily · 5.8.2026
Glaukos Corporation (GKOS) currently has a StockIQ AI score of 49/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
GKOS currently scores 49/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, GKOS's estimated fair value is -$9.40, which is 105.7% below the current price of $163.81. This is one valuation model among several signals in the fair-value category, not a price target.
GKOS's technical score is 39/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 32.3%; Free cash flow growth: 66.8%; Operating margin is stable or improving over time.
Based on the real signals StockIQ computed: Estimated fair value: -$9.40 vs. price $163.81 (-105.7%); Operating margin: -39.3% (negative); Net margin: -37.0% (negative).
StockIQ has no recorded dividend payment history for GKOS.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 8 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Navratil Tomas | Open Market Sale | 28.8.2026 | 10 | -10 | $182.50 |
| Navratil Tomas | Open Market Sale | 28.8.2026 | 7,643 | -7,643 | $180.25 |
| Navratil Tomas | Open Market Sale | 28.8.2026 | 6,091 | -6,091 | $181.19 |
| Kliman Gilbert H | Exercise of Derivative Securities | 19.8.2026 | 2,500 | -2,500 | — |
| Kliman Gilbert H | Open Market Sale | 19.8.2026 | 2,500 | -2,500 | $190.00 |
| Kliman Gilbert H | Exercise of Derivative Securities | 19.8.2026 | 2,500 | +2,500 | $25.77 |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 20,000 | +20,000 | $55.18 |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 10,000 | -10,000 | — |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 20,000 | -20,000 | — |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 20,000 | +20,000 | $55.18 |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 10,000 | +10,000 | $48.46 |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 10,000 | +10,000 | $48.46 |
| Gilliam Joseph E | Open Market Sale | 11.8.2026 | 27,963 | -27,963 | $178.89 |
| Gilliam Joseph E | Open Market Sale | 11.8.2026 | 32,037 | -32,037 | $180.49 |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 20,000 | -20,000 | — |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 10,000 | -10,000 | — |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 82,588 | +10,000 | $48.46 |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 122,588 | +20,000 | $55.18 |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 102,588 | +20,000 | $55.18 |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 132,588 | +10,000 | $48.46 |
| Gilliam Joseph E | Open Market Sale | 11.8.2026 | 104,625 | -27,963 | $178.89 |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 26,751 | -10,000 | — |
| Gilliam Joseph E | Open Market Sale | 11.8.2026 | 72,588 | -32,037 | $180.49 |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 33,118 | -20,000 | — |
| Gilliam Joseph E | Exercise of Derivative Securities | 11.8.2026 | 51,475 | -20,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
3,821,554 shares short as of 2026-08-31 · vs. 3,626,381 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
55.9% of trading volume this week was short selling, vs. 50.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology